Status:

COMPLETED

Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen

Lead Sponsor:

Centre Hospitalier Universitaire Dijon

Conditions:

COVID-19 Severe Pneumonia

Severe Pneumonia Due to Other Pathogene

Eligibility:

All Genders

18+ years

Brief Summary

SARS-COV 2 infection might be responsible for sever pneumonia. Obesity seems to be a risk factor for severe SARS-COV 2 pneumonia. Lipid metabolism alteration are described with both obesity and sepsis...

Eligibility Criteria

Inclusion

  • 2 of the following criteria: Cough/ Dyspnea/ Spitting/ Thoracic pain/ Hyperthermia (\>=38 °C) Hypothermia (\< 35°C) AND new radiologic pulmonary infiltrate
  • At admission or within 48 hours following hospital admission
  • With 2 qSOFA criteria: MAP =\< 100 mmHg, Respiratory Rate \>= 22, Glasgow score \< 15 OR on mechanical ventilation OR under vasopressor
  • Age \> 18
  • affiliated to social security

Exclusion

  • Pregnancy
  • immunodepression
  • Pathology known to cause severe lymphopenia
  • hospitalisation within 3 month before inclusion AND sepsis

Key Trial Info

Start Date :

April 7 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 7 2020

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT04435223

Start Date

April 7 2020

End Date

May 7 2020

Last Update

June 23 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chu Dijon Bourgogne

Dijon, France, 21000